Cargando…

Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ)

PURPOSE: Pazopanib has promising antiangiogenetic activity in solid cancers. The investigator-initiated phase I/II trial evaluated the combination of Topotecan with Pazopanib in platinum-resistant or intermediate-sensitive recurrent ovarian cancer (ROC). METHODS: Patients (≥ 18 years) with first or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chekerov, Radoslav, Arndt, Tjadina, Pietzner, Klaus, Canzler, Ulrich, Wimberger, Pauline, Strauß, Hans-Georg, Mahner, Sven, Woelber, Linn, de Gregorio, Nikolaus, Stocker, Gertraud, von Abel, Ekkehard, Neunhoeffer, Tanja, Belau, Antje Kristina, Mustea, Alexander, Yalinkaya, Isil, Braicu, Elena Ioana, Richter, Rolf, Sehouli, Jalid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374680/ https://www.ncbi.nlm.nih.gov/pubmed/37000264 http://dx.doi.org/10.1007/s00432-023-04647-9

Ejemplares similares

Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group
por: Trillsch, Fabian, et al.
Publicado: (2021)

Preference of elderly patients’ to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial
por: Chekerov, Radoslav, et al.
Publicado: (2017)

Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial
por: Manji, Arif, et al.
Publicado: (2022)

Can a morphological description of the peritoneal carcinomatosis in advanced ovarian cancer add prognostic information? Analysis of 1686 patients of the tumor bank ovarian cancer
por: Nasser, Sara, et al.
Publicado: (2022)

Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium
por: Trillsch, Fabian, et al.
Publicado: (2013)

Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells
por: Di Desidero, Teresa, et al.
Publicado: (2019)

Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) – a study of the TOC Consortium
por: Braicu, Elena Ioana, et al.
Publicado: (2014)

Topaze : pièce en quatre actes
por: Pagnol, Marcel

KEK: Testing TOPAZ
Publicado: (1985)

Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancer—Impact for Diagnosis and Treatment Monitoring
por: Braicu, Elena Ioana, et al.
Publicado: (2021)

KEK : Essais de TOPAZ
Publicado: (1985)

Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours
por: Kerklaan, B Milojkovic, et al.
Publicado: (2015)

The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer—A Study of the OVCAD Consortium
por: Obermayr, Eva, et al.
Publicado: (2021)

Muon trigger system in the TOPAZ detector
por: Ujiie, N, et al.
Publicado: (1995)

Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancer—A Study of the OVCAD Consortium
por: Obermayr, Eva, et al.
Publicado: (2021)

Discovery and Validation of Novel Biomarkers for Detection of Epithelial Ovarian Cancer
por: Kulbe, Hagen, et al.
Publicado: (2019)

Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer
por: Woopen, Hannah, et al.
Publicado: (2014)

Estimation of beam backgrounds for the TOPAZ vertex chamber
por: Tauchi, T, et al.
Publicado: (1990)

Fertility-Sparing Surgery in Early Epithelial Ovarian Cancer: A Viable Option?
por: Fotopoulou, Christina, et al.
Publicado: (2012)

Pseudo- or real progression? An ovarian cancer patient under nivolumab: A case report
por: Passler, Mona, et al.
Publicado: (2019)

Single crystal elasticity of natural topaz at high-temperatures
por: Tennakoon, Sumudu, et al.
Publicado: (2018)

Stable expansion of high‐grade serous ovarian cancer organoids requires a low‐Wnt environment
por: Hoffmann, Karen, et al.
Publicado: (2020)

F/OH ratio in a rare fluorine-poor blue topaz from Padre Paraíso (Minas Gerais, Brazil) to unravel topaz’s ambient of formation
por: Precisvalle, N., et al.
Publicado: (2021)

Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium
por: Aust, Stefanie, et al.
Publicado: (2012)

A New Detailed Term Accounting Opacity Code: TOPAZ
por: Iglesias, C A, et al.
Publicado: (2004)

Sialic Acid Linkage Analysis Refines the Diagnosis of Ovarian Cancer
por: Dědová, Tereza, et al.
Publicado: (2019)

Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer
por: Di Desidero, Teresa, et al.
Publicado: (2015)

TOPAZ: asymmetric suffix array neighbourhood search for massive protein databases
por: Medlar, Alan, et al.
Publicado: (2018)

Bevacizumab Combined with Platinum–Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 Patients
por: Sehouli, Jalid, et al.
Publicado: (2021)

Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer
por: Mungenast, Felicitas, et al.
Publicado: (2017)

The Serum Glycome to Discriminate between Early-Stage Epithelial Ovarian Cancer and Benign Ovarian Diseases
por: Biskup, Karina, et al.
Publicado: (2014)

Chondroitin Sulfate Disaccharides, a Serum Marker for Primary Serous Epithelial Ovarian Cancer
por: Biskup, Karina, et al.
Publicado: (2021)

HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients
por: Braicu, Elena Ioana, et al.
Publicado: (2022)

Topaz-Denoise: general deep denoising models for cryoEM and cryoET
por: Bepler, Tristan, et al.
Publicado: (2020)

Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers
por: Braicu, E-I, et al.
Publicado: (2011)

A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis
por: Mahner, Sven, et al.
Publicado: (2012)

A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO)
por: Sehouli, Jalid, et al.
Publicado: (2016)

Pelvic Lymphadenectomy in Vulvar Cancer – Does it make sense?
por: Woelber, Linn, et al.
Publicado: (2020)

Propensity Scoring after Multiple Imputation in a Retrospective Study on Adjuvant Radiation Therapy in Lymph-Node Positive Vulvar Cancer
por: Eulenburg, Christine, et al.
Publicado: (2016)

Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients
por: Gericke, Beate, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_1nued86v402f7kiu7vsn12soq9